• Japanese
  • Korean
  • Chinese
Cover Image

Pediatrics Partnering Terms and Agreements

The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatrics partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatrics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pediatrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pediatrics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual pediatrics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of pediatrics dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in pediatrics dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading pediatrics deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of pediatrics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all pediatrics deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all pediatrics partnering deals signed and announced since 2009. The chapter is organized by specific pediatrics therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all pediatrics partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in pediatrics partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pediatrics technologies and products.

Benefits

Pediatrics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of pediatrics deal trends since 2009
  • Access pediatrics deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between pediatrics partner companies
  • Comprehensive access to over 500 links to actual pediatrics deals entered into by the world's biopharma companies
  • Indepth review of pediatrics deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner pediatrics opportunities
  • Uncover companies actively partnering pediatrics opportunities

Report scope

  • Pediatrics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pediatrics trends and structure of deals entered into by leading companies worldwide.

Pediatrics Partnering Terms and Agreements includes:

  • Trends in pediatrics dealmaking in the biopharma industry since 2009
  • Analysis of pediatrics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of pediatrics deal contract documents
  • Comprehensive access to over 500 pediatrics deal records
  • The leading pediatrics deals by value since 2009
  • Most active pediatrics dealmakers since 2009

In Pediatrics Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in pediatrics dealmaking

  • 2.1. Introduction
  • 2.2. Pediatrics partnering over the years
  • 2.3. Bigpharma pediatrics dealmaking activity
  • 2.4. Bigpharma not active in pediatrics
  • 2.5. Pediatrics partnering by deal type
  • 2.6. Pediatrics partnering by industry sector
  • 2.7. Pediatrics partnering by stage of development
  • 2.8. Pediatrics partnering by technology type
  • 2.9. Pediatrics partnering by pediatrics indication
  • 2.10. Average deal terms for pediatrics
    • 2.10.1 Pediatrics headline values
    • 2.10.2 Pediatrics upfront payments
    • 2.10.3 Pediatrics milestone payments
    • 2.10.4 Pediatrics royalty rates

Chapter 3 - Leading Pediatrics deals

  • 3.1. Introduction
  • 3.2. Top Pediatrics deals by value
  • 3.3. Top Pediatrics deals involving bigpharma

Chapter 4 - Bigpharma pediatrics deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma pediatrics partnering company profiles
  • Abbott
  • Allergan
  • AstraZeneca
  • Baxter International
  • Biogen Idec
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eisai
  • Forest Laboratories
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co
  • Merck KGaA
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Shionogi
  • Teva

Chapter 5 - Pediatrics partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
  • Collaborative R&D
  • Contract service
  • Co-promotion
  • Development
  • Distribution
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Supply
  • 5.3. By stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase III
  • Marketed
  • 5.4. By technology type
  • Assays
  • Biological compounds
  • Discovery tools
  • Drug delivery
  • Genomics
  • Natural product
  • Orphan drug
  • Peptides
  • Screening
  • Small molecules

Chapter 6 - Pediatrics dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
  • Anaesthetics
  • Cardiovascular
  • Central Nervous System
  • Cosmetics
  • Dental
  • Dermatology
  • Gastrointestinal
  • Genetic disorders
  • Genitourinary
  • Gynaecology
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Pediatrics
  • Psychiatry
  • Respiratory

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of pediatrics deals by company A-Z 2009-2014
  • Appendix 2 - Directory of pediatrics deals by deal type 2009-2014
  • Appendix 3 - Directory of pediatrics deals by stage of development 2009-2014
  • Appendix 4 - Directory of pediatrics deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Therapy Reports
  • Table of figures
  • Figure 1: Pediatrics partnering since 2009
  • Figure 2: Bigpharma - top 50 - pediatrics deals 2009 to 2012
  • Figure 3: Bigpharma pediatrics deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in pediatrics 2009-2014
  • Figure 5: Pediatrics partnering by deal type since 2009
  • Figure 6: Pediatrics partnering by industry sector since 2009
  • Figure 7: Pediatrics partnering by stage of development since 2009
  • Figure 8: Pediatrics partnering by technology type since 2009
  • Figure 9: Pediatrics partnering by pediatrics target since 2009
  • Figure 10: Pediatrics deals with a headline value
  • Figure 11: Pediatrics deal headline value distribution, US$million - discovery stage
  • Figure 12: Pediatrics deal headline value distribution, US$million - preclinical stage
  • Figure 13: Pediatrics deal headline value distribution, US$million - phase I stage
  • Figure 14: Pediatrics deal headline value distribution, US$million - phase II stage
  • Figure 15: Pediatrics deal headline value distribution, US$million - phase III stage
  • Figure 16: Pediatrics deal headline value distribution, US$million - regulatory stage
  • Figure 17: Pediatrics deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19 Pediatrics deals with upfront payment values
  • Figure 20: Pediatrics deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Pediatrics deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Pediatrics deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Pediatrics deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Pediatrics deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Pediatrics deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Pediatrics deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Pediatrics deals with milestone payments
  • Figure 29: Pediatrics deal milestone distribution, US$million - discovery stage
  • Figure 30: Pediatrics deal milestone distribution, US$million - preclinical stage
  • Figure 31: Pediatrics deal milestone distribution, US$million - phase I stage
  • Figure 32: Pediatrics deal milestone distribution, US$million - phase II stage
  • Figure 33: Pediatrics deal milestone distribution, US$million - phase III stage
  • Figure 34: Pediatrics deal milestone distribution, US$million - regulatory stage
  • Figure 35: Pediatrics deal milestone distribution, US$million - marketed stage
  • Figure 36: Pediatrics health deals with royalty rates, %
  • Figure 37: Pediatrics deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Pediatrics deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Pediatrics deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Pediatrics deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Pediatrics deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Pediatrics deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top pediatrics deals by value since 2009
  • Figure 46: Top pediatrics deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing
Get Notified
Email me when related reports are published